What is TB-500?
TB-500 is a peptide comprised of a 7 amino acid fragment of the naturally occurring thymosin beta-4. It is thought to have functions in tissue repair and inflammation control by modulating the cell cytoskeleton.
How Does TB-500 Work?
TB-500 is a synthetic fragment of the larger thymosin beta 4 (TB4) peptide, made up of a specific 7 amino acid sequence that is most closely linked to actin interaction.
Because of this connection to actin, a key component of the cytoskeleton, TB-500 helps reorganize the cell’s structural framework, allowing regenerating cells to move into position after tissue damage. Beyond cell movement, TB-500 has also been shown to promote the growth of new blood vessels following injury, which helps deliver nutrients and other materials needed for repair to the damaged area.
Researchers are also exploring TB-500’s potential ability to direct inflammatory cells to clear debris at the site of injury, helping create a cleaner environment that supports the healing process.
What is TB-500 Used for?
Avenues of research interest for TB-500 include:
- Muscle and tendon repair
- Injury recovery
- Wound healing and inflammation control
Side Effects of TB-500
TB-500 has demonstrated low toxicity in animal studies, which is presumed to similarly translate to humans, but human studies are sparse.
TB-500 Dosing Protocol (for Research)
Independent researchers vary in their recommended dosage and frequency for TB-500. However, one possible dosing algorithm is the following:
| Phase | Dose & frequency |
|---|---|
| Weeks 1-4 (treatment phase) | 2.5 mg twice weekly |
| Week 5 and beyond (maintenance phase) | 0.25 mg/day |
Shown for education. A licensed clinician should set any actual dose. Compare protocols across peptides in the peptide dosage chart.
Common questions about TB-500
What is TB-500?
TB-500 is a peptide comprised of a 7 amino acid fragment of the naturally occurring thymosin beta-4. It is thought to have functions in tissue repair and inflammation control by modulating the cell cytoskeleton.
What is TB-500 used for?
Areas studied include: Muscle and tendon repair; Injury recovery; Wound healing and inflammation control.
How does TB-500 work?
TB-500 is a synthetic fragment of the larger thymosin beta 4 (TB4) peptide, made up of a specific 7 amino acid sequence that is most closely linked to actin interaction.
What are the side effects of TB-500?
TB-500 has demonstrated low toxicity in animal studies, which is presumed to similarly translate to humans, but human studies are sparse.
What is the dosage of TB-500?
One commonly referenced research protocol is: Weeks 1-4 (treatment phase): 2.5 mg twice weekly; Week 5 and beyond (maintenance phase): 0.25 mg/day. Shown for education only; a licensed clinician should set any actual dose. See the dosing table.
How do you mix (reconstitute) TB-500?
Wipe the vial tops with alcohol, add bacteriostatic water slowly so it runs down the inside of the glass, then roll the vial gently until the powder dissolves; don’t shake it. See the step-by-step guide with diagrams for the pen and syringe methods.
How much bacteriostatic water do you add to TB-500?
There is no single correct amount. We recommend 2.1 mL: about 0.1 mL is lost during transfer, leaving roughly 2.0 mL of usable solution. You can add more or less (most peptide vials hold up to 3 mL); just enter the amount in the dose calculator. See the step-by-step mixing guide.
Is TB-500 FDA-approved?
No. TB-500 is not FDA-approved in the US (status as of October 2026).
References
- Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012 Jan;12:37-51. doi: 10.1517/14712598.2012.634793. View source
- Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002 Feb;74(2):293-9. doi: 10.1006/exer.2001.1125. PMID: 11950239. View source
- Smart N, et al. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10:229-41. doi: 10.1007/s10456-007-9077-x. View source